<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31596526</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>23</Day></DateCompleted><DateRevised><Year>2020</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-1136</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>2</Issue><PubDate><Year>2020</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Glia</Title><ISOAbbreviation>Glia</ISOAbbreviation></Journal><ArticleTitle>The microglial NLRP3 inflammasome is activated by amyotrophic lateral sclerosis proteins.</ArticleTitle><Pagination><StartPage>407</StartPage><EndPage>421</EndPage><MedlinePgn>407-421</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/glia.23728</ELocationID><Abstract><AbstractText>Microglial NLRP3 inflammasome activation is emerging as a key contributor to neuroinflammation during neurodegeneration. Pathogenic protein aggregates such as &#x3b2;-amyloid and &#x3b1;-synuclein trigger microglial NLRP3 activation, leading to caspase-1 activation and IL-1&#x3b2; secretion. Both caspase-1 and IL-1&#x3b2; contribute to disease progression in the mouse SOD1<sup>G93A</sup> model of amyotrophic lateral sclerosis (ALS), suggesting a role for microglial NLRP3. Prior studies, however, suggested SOD1<sup>G93A</sup> mice microglia do not express NLRP3, and SOD1<sup>G93A</sup> protein generated IL-1&#x3b2; in microglia independent to NLRP3. Here, we demonstrate using Nlrp3-GFP gene knock-in mice that microglia express NLRP3 in SOD1<sup>G93A</sup> mice. We show that both aggregated and soluble SOD1<sup>G93A</sup> activates inflammasome in primary mouse microglia leading caspase-1 and IL-1&#x3b2; cleavage, ASC speck formation, and the secretion of IL-1&#x3b2; in a dose- and time-dependent manner. Importantly, SOD1<sup>G93A</sup> was unable to induce IL-1&#x3b2; secretion from microglia deficient for Nlrp3, or pretreated with the specific NLRP3 inhibitor MCC950, confirming NLRP3 as the key inflammasome complex mediating SOD1-induced microglial IL-1&#x3b2; secretion. Microglial NLRP3 upregulation was also observed in the TDP-43<sup>Q331K</sup> ALS mouse model, and TDP-43 wild-type and mutant proteins could also activate microglial inflammasomes in a NLRP3-dependent manner. Mechanistically, we identified the generation of reactive oxygen species and ATP as key events required for SOD1<sup>G93A</sup> -mediated NLRP3 activation. Taken together, our data demonstrate that ALS microglia express NLRP3, and that pathological ALS proteins activate the microglial NLRP3 inflammasome. NLRP3 inhibition may therefore be a potential therapeutic approach to arrest microglial neuroinflammation and ALS disease progression.</AbstractText><CopyrightInformation>&#xa9; 2019 Wiley Periodicals, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Deora</LastName><ForeName>Vandana</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>School of Biomedical Sciences, Faculty of Medicine, The University of Queensland, St. Lucia, Queensland, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>John D</ForeName><Initials>JD</Initials><Identifier Source="ORCID">0000-0002-9976-7396</Identifier><AffiliationInfo><Affiliation>School of Biomedical Sciences, Faculty of Medicine, The University of Queensland, St. Lucia, Queensland, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Queensland Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Herston, Queensland, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albornoz</LastName><ForeName>Eduardo A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>School of Biomedical Sciences, Faculty of Medicine, The University of Queensland, St. Lucia, Queensland, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Molecular Bioscience, and Centre for Inflammation and Disease Research, The University of Queensland, St. Lucia, Queensland, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McAlary</LastName><ForeName>Luke</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>School of Chemistry and Molecular Biosciences, Faculty of Science, Medicine and Health, University of Wollongong, Wollongong, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Illawarra Health and Medical Institute, University of Wollongong, Wollongong, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jagaraj</LastName><ForeName>Cyril J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and Health Sciences, Department of Biomedical Sciences, Centre for MND Research, Macquarie University, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robertson</LastName><ForeName>Avril A B</ForeName><Initials>AAB</Initials><AffiliationInfo><Affiliation>Institute for Molecular Bioscience, and Centre for Inflammation and Disease Research, The University of Queensland, St. Lucia, Queensland, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Chemistry and Molecular Biosciences, The University of Queensland, St. Lucia, Queensland, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atkin</LastName><ForeName>Julie D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and Health Sciences, Department of Biomedical Sciences, Centre for MND Research, Macquarie University, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cooper</LastName><ForeName>Matthew A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Institute for Molecular Bioscience, and Centre for Inflammation and Disease Research, The University of Queensland, St. Lucia, Queensland, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schroder</LastName><ForeName>Kate</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute for Molecular Bioscience, and Centre for Inflammation and Disease Research, The University of Queensland, St. Lucia, Queensland, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yerbury</LastName><ForeName>Justin J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>School of Chemistry and Molecular Biosciences, Faculty of Science, Medicine and Health, University of Wollongong, Wollongong, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Illawarra Health and Medical Institute, University of Wollongong, Wollongong, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gordon</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>School of Biomedical Sciences, Faculty of Medicine, The University of Queensland, St. Lucia, Queensland, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Queensland Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Herston, Queensland, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woodruff</LastName><ForeName>Trent M</ForeName><Initials>TM</Initials><Identifier Source="ORCID">0000-0003-1382-911X</Identifier><AffiliationInfo><Affiliation>School of Biomedical Sciences, Faculty of Medicine, The University of Queensland, St. Lucia, Queensland, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>10</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Glia</MedlineTA><NlmUniqueID>8806785</NlmUniqueID><ISSNLinking>0894-1491</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058847">Inflammasomes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071199">NLR Family, Pyrin Domain-Containing 3 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C453881">NLRP3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C492716">Nlrp3 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Glia. 2020 Oct;68(10):2167-2168</RefSource><PMID Version="1">32776647</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058847" MajorTopicYN="N">Inflammasomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071199" MajorTopicYN="N">NLR Family, Pyrin Domain-Containing 3 Protein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">IL-1&#x3b2;</Keyword><Keyword MajorTopicYN="N">glia</Keyword><Keyword MajorTopicYN="N">innate immunity</Keyword><Keyword MajorTopicYN="N">motor neuron disease</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>10</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>10</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31596526</ArticleId><ArticleId IdType="doi">10.1002/glia.23728</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Alexianu, M. E., Kozovska, M., &amp; Appel, S. H. (2001). Immune reactivity in a mouse model of familial ALS correlates with disease progression. Neurology, 57(7), 1282-1289. https://doi.org/10.1212/wnl.57.7.1282</Citation></Reference><Reference><Citation>Anderson, V. L., &amp; Webb, W. W. (2011). Transmission electron microscopy characterization of fluorescently labelled amyloid beta 1-40 and alpha-synuclein aggregates. BMC Biotechnology, 11, 125. https://doi.org/10.1186/1472-6750-11-125</Citation></Reference><Reference><Citation>Apolloni, S., Parisi, C., Pesaresi, M. G., Rossi, S., Carri, M. T., Cozzolino, M., &#x2026; D'Ambrosi, N. (2013). The NADPH oxidase pathway is dysregulated by the P2X7 receptor in the SOD1-G93A microglia model of amyotrophic lateral sclerosis. Journal of Immunology, 190(10), 5187-5195. https://doi.org/10.4049/jimmunol.1203262</Citation></Reference><Reference><Citation>Arnold, E. S., Ling, S. C., Huelga, S. C., Lagier-Tourenne, C., Polymenidou, M., Ditsworth, D., &#x2026; Cleveland, D. W. (2013). ALS-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-43. Proceedings of the National Academy of Sciences of the United States of America, 110(8), E736-E745. https://doi.org/10.1073/pnas.1222809110</Citation></Reference><Reference><Citation>Barmada, S. J., Skibinski, G., Korb, E., Rao, E. J., Wu, J. Y., &amp; Finkbeiner, S. (2010). Cytoplasmic mislocalization of TDP-43 is toxic to neurons and enhanced by a mutation associated with familial amyotrophic lateral sclerosis. The Journal of Neuroscience, 30(2), 639-649. https://doi.org/10.1523/JNEUROSCI.4988-09.2010</Citation></Reference><Reference><Citation>Bellezza, I., Grottelli, S., Costanzi, E., Scarpelli, P., Pigna, E., Morozzi, G., &#x2026; Minelli, A. (2018). Peroxynitrite activates the NLRP3 inflammasome cascade in SOD1(G93A) mouse model of amyotrophic lateral sclerosis. Molecular Neurobiology, 55(3), 2350-2361. https://doi.org/10.1007/s12035-017-0502-x</Citation></Reference><Reference><Citation>Brites, D., &amp; Vaz, A. R. (2014). Microglia centered pathogenesis in ALS: Insights in cell interconnectivity. Frontiers in Cellular Neuroscience, 8, 117. https://doi.org/10.3389/fncel.2014.00117</Citation></Reference><Reference><Citation>Burm, S. M., Zuiderwijk-Sick, E. A., t Jong, A. E., van der Putten, C., Veth, J., Kondova, I., &amp; Bajramovic, J. J. (2015). Inflammasome-induced IL-1beta secretion in microglia is characterized by delayed kinetics and is only partially dependent on inflammatory caspases. The Journal of Neuroscience, 35(2), 678-687. https://doi.org/10.1523/JNEUROSCI.2510-14.2015</Citation></Reference><Reference><Citation>Codolo, G., Plotegher, N., Pozzobon, T., Brucale, M., Tessari, I., Bubacco, L., &amp; de Bernard, M. (2013). Triggering of inflammasome by aggregated alpha-synuclein, an inflammatory response in synucleinopathies. PLoS One, 8(1), e55375. https://doi.org/10.1371/journal.pone.0055375</Citation></Reference><Reference><Citation>Coll, R. C., Robertson, A. A., Chae, J. J., Higgins, S. C., Munoz-Planillo, R., Inserra, M. C., &#x2026; O'Neill, L. A. (2015). A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nature Medicine, 21(3), 248-255. https://doi.org/10.1038/nm.3806</Citation></Reference><Reference><Citation>Debye, B., Schmulling, L., Zhou, L., Rune, G., Beyer, C., &amp; Johann, S. (2018). Neurodegeneration and NLRP3 inflammasome expression in the anterior thalamus of SOD1(G93A) ALS mice. Brain Pathology, 28(1), 14-27. https://doi.org/10.1111/bpa.12467</Citation></Reference><Reference><Citation>Deora, V., Albornoz, E. A., Zhu, K., Woodruff, T. M., &amp; Gordon, R. (2017). The ketone body beta-hydroxybutyrate does not inhibit synuclein mediated inflammasome activation in microglia. Journal of Neuroimmune Pharmacology, 12(4), 568-574. https://doi.org/10.1007/s11481-017-9754-5</Citation></Reference><Reference><Citation>Eschenfeldt, W. H., Lucy, S., Millard, C. S., Joachimiak, A., &amp; Mark, I. D. (2009). A family of LIC vectors for high-throughput cloning and purification of proteins. Methods in Molecular Biology, 498, 105-115. https://doi.org/10.1007/978-1-59745-196-3_7</Citation></Reference><Reference><Citation>Forsberg, K., Graffmo, K., Pakkenberg, B., Weber, M., Nielsen, M., Marklund, S., &#x2026; Andersen, P. M. (2019). Misfolded SOD1 inclusions in patients with mutations in C9orf72 and other ALS/FTD-associated genes. Journal of Neurology, Neurosurgery, and Psychiatry, 90, 861-869. https://doi.org/10.1136/jnnp-2018-319386</Citation></Reference><Reference><Citation>Friedlander, R. M., Brown, R. H., Gagliardini, V., Wang, J., &amp; Yuan, J. (1997). Inhibition of ICE slows ALS in mice. Nature, 388(6637), 31. https://doi.org/10.1038/40299</Citation></Reference><Reference><Citation>Gaidt, M. M., Ebert, T. S., Chauhan, D., Schmidt, T., Schmid-Burgk, J. L., Rapino, F., &#x2026; Hornung, V. (2016). Human monocytes engage an alternative inflammasome pathway. Immunity, 44(4), 833-846. https://doi.org/10.1016/j.immuni.2016.01.012</Citation></Reference><Reference><Citation>Geevasinga, N., Menon, P., Ng, K., Van Den Bos, M., Byth, K., Kiernan, M. C., &amp; Vucic, S. (2016). Riluzole exerts transient modulating effects on cortical and axonal hyperexcitability in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 17(1-9), 580-588. https://doi.org/10.1080/21678421.2016.1188961</Citation></Reference><Reference><Citation>Gombault, A., Baron, L., &amp; Couillin, I. (2012). ATP release and purinergic signaling in NLRP3 inflammasome activation. Frontiers in Immunology, 3, 414. https://doi.org/10.3389/fimmu.2012.00414</Citation></Reference><Reference><Citation>Gordon, R., Albornoz, E. A., Christie, D. C., Langley, M. R., Kumar, V., Mantovani, S., &#x2026; Woodruff, T. M. (2018). Inflammasome inhibition prevents alpha-synuclein pathology and dopaminergic neurodegeneration in mice. Science Translational Medicine, 10(465), eaah4066. https://doi.org/10.1126/scitranslmed.aah4066</Citation></Reference><Reference><Citation>Gordon, R., Hogan, C. E., Neal, M. L., Anantharam, V., Kanthasamy, A. G., &amp; Kanthasamy, A. (2011). A simple magnetic separation method for high-yield isolation of pure primary microglia. Journal of Neuroscience Methods, 194(2), 287-296. https://doi.org/10.1016/j.jneumeth.2010.11.001</Citation></Reference><Reference><Citation>Gross, C. J., Mishra, R., Schneider, K. S., Medard, G., Wettmarshausen, J., Dittlein, D. C., &#x2026; Gross, O. (2016). K(+) efflux-independent NLRP3 inflammasome activation by small molecules targeting mitochondria. Immunity, 45(4), 761-773. https://doi.org/10.1016/j.immuni.2016.08.010</Citation></Reference><Reference><Citation>Guarda, G., Zenger, M., Yazdi, A. S., Schroder, K., Ferrero, I., Menu, P., &#x2026; Tschopp, J. (2011). Differential expression of NLRP3 among hematopoietic cells. Journal of Immunology, 186(4), 2529-2534. https://doi.org/10.4049/jimmunol.1002720</Citation></Reference><Reference><Citation>Gugliandolo, A., Giacoppo, S., Bramanti, P., &amp; Mazzon, E. (2018). NLRP3 inflammasome activation in a transgenic amyotrophic lateral sclerosis model. Inflammation, 41(1), 93-103. https://doi.org/10.1007/s10753-017-0667-5</Citation></Reference><Reference><Citation>Guo, H., Callaway, J. B., &amp; Ting, J. P. Y. (2015). Inflammasomes: Mechanism of action, role in disease, and therapeutics. Nature Medicine, 21(7), 677-687. https://doi.org/10.1038/nm.3893</Citation></Reference><Reference><Citation>Gurney, M. E., Pu, H., Chiu, A. Y., Dal Canto, M. C., Polchow, C. Y., Alexander, D. D., &#x2026; Deng, H. X. (1994). Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science, 264(5166), 1772-1775. https://doi.org/10.1126/science.8209258</Citation></Reference><Reference><Citation>Gustin, A., Kirchmeyer, M., Koncina, E., Felten, P., Losciuto, S., Heurtaux, T., &#x2026; Dostert, C. (2015). NLRP3 inflammasome is expressed and functional in mouse brain microglia but not in astrocytes. PLoS One, 10(6), e0130624. https://doi.org/10.1371/journal.pone.0130624</Citation></Reference><Reference><Citation>Harijith, A., Ebenezer, D. L., &amp; Natarajan, V. (2014). Reactive oxygen species at the crossroads of inflammasome and inflammation. Frontiers in Physiology, 5, 352. https://doi.org/10.3389/fphys.2014.00352</Citation></Reference><Reference><Citation>Heneka, M. T., Kummer, M. P., Stutz, A., Delekate, A., Schwartz, S., Vieira-Saecker, A., &#x2026; Golenbock, D. T. (2013). NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature, 493(7434), 674-678. https://doi.org/10.1038/nature11729</Citation></Reference><Reference><Citation>Hensley, K., Abdel-Moaty, H., Hunter, J., Mhatre, M., Mou, S., Nguyen, K., &#x2026; West, M. (2006). Primary glia expressing the G93A-SOD1 mutation present a neuroinflammatory phenotype and provide a cellular system for studies of glial inflammation. Journal of Neuroinflammation, 3, 2. https://doi.org/10.1186/1742-2094-3-2</Citation></Reference><Reference><Citation>Johann, S., Heitzer, M., Kanagaratnam, M., Goswami, A., Rizo, T., Weis, J., &#x2026; Beyer, C. (2015). NLRP3 inflammasome is expressed by astrocytes in the SOD1 mouse model of ALS and in human sporadic ALS patients. Glia, 63(12), 2260-2273. https://doi.org/10.1002/glia.22891</Citation></Reference><Reference><Citation>Knibb, J. A., Keren, N., Kulka, A., Leigh, P. N., Martin, S., Shaw, C. E., &#x2026; Al-Chalabi, A. (2016). A clinical tool for predicting survival in ALS. Journal of Neurology, Neurosurgery, and Psychiatry, 87(12), 1361-1367. https://doi.org/10.1136/jnnp-2015-312908</Citation></Reference><Reference><Citation>Lee, J. D., Kamaruzaman, N. A., Fung, J. N., Taylor, S. M., Turner, B. J., Atkin, J. D., &#x2026; Noakes, P. G. (2013). Dysregulation of the complement cascade in the hSOD1G93A transgenic mouse model of amyotrophic lateral sclerosis. Journal of Neuroinflammation, 10, 119. https://doi.org/10.1186/1742-2094-10-119</Citation></Reference><Reference><Citation>Lee, J. D., Kumar, V., Fung, J. N., Ruitenberg, M. J., Noakes, P. G., &amp; Woodruff, T. M. (2017). Pharmacological inhibition of complement C5a-C5a1 receptor signalling ameliorates disease pathology in the hSOD1(G93A) mouse model of amyotrophic lateral sclerosis. British Journal of Pharmacology, 174(8), 689-699. https://doi.org/10.1111/bph.13730</Citation></Reference><Reference><Citation>Lee, J. D., Levin, S. C., Willis, E. F., Li, R., Woodruff, T. M., &amp; Noakes, P. G. (2018). Complement components are upregulated and correlate with disease progression in the TDP-43(Q331K) mouse model of amyotrophic lateral sclerosis. Journal of Neuroinflammation, 15(1), 171. https://doi.org/10.1186/s12974-018-1217-2</Citation></Reference><Reference><Citation>Li, M., Ona, V. O., Guegan, C., Chen, M., Jackson-Lewis, V., Andrews, L. J., &#x2026; Friedlander, R. M. (2000). Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science, 288(5464), 335-339. https://doi.org/10.1126/science.288.5464.335</Citation></Reference><Reference><Citation>Martin-Sanchez, F., Diamond, C., Zeitler, M., Gomez, A. I., Baroja-Mazo, A., Bagnall, J., &#x2026; Pelegrin, P. (2016). Inflammasome-dependent IL-1beta release depends upon membrane permeabilisation. Cell Death and Differentiation, 23(7), 1219-1231. https://doi.org/10.1038/cdd.2015.176</Citation></Reference><Reference><Citation>Martinon, F., Petrilli, V., Mayor, A., Tardivel, A., &amp; Tschopp, J. (2006). Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature, 440(7081), 237-241. https://doi.org/10.1038/nature04516</Citation></Reference><Reference><Citation>McAlary, L., Aquilina, J. A., &amp; Yerbury, J. J. (2016). Susceptibility of mutant SOD1 to form a destabilized monomer predicts cellular aggregation and toxicity but not in vitro aggregation propensity. Frontiers in Neuroscience, 10, 499. https://doi.org/10.3389/fnins.2016.00499</Citation></Reference><Reference><Citation>Meissner, F., Molawi, K., &amp; Zychlinsky, A. (2010). Mutant superoxide dismutase 1-induced IL-1beta accelerates ALS pathogenesis. Proceedings of the National Academy of Sciences of the United States of America, 107(29), 13046-13050. https://doi.org/10.1073/pnas.1002396107</Citation></Reference><Reference><Citation>Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C., Chou, T. T., &#x2026; Lee, V. M. (2006). Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science, 314(5796), 130-133. https://doi.org/10.1126/science.1134108</Citation></Reference><Reference><Citation>Nguyen, M. D., Julien, J. P., &amp; Rivest, S. (2001). Induction of proinflammatory molecules in mice with amyotrophic lateral sclerosis: No requirement for proapoptotic interleukin-1beta in neurodegeneration. Annals of Neurology, 50(5), 630-639.</Citation></Reference><Reference><Citation>Paez-Colasante, X., Figueroa-Romero, C., Sakowski, S. A., Goutman, S. A., &amp; Feldman, E. L. (2015). Amyotrophic lateral sclerosis: Mechanisms and therapeutics in the epigenomic era. Nature Reviews. Neurology, 11(5), 266-279. https://doi.org/10.1038/nrneurol.2015.57</Citation></Reference><Reference><Citation>Parajuli, B., Sonobe, Y., Horiuchi, H., Takeuchi, H., Mizuno, T., &amp; Suzumura, A. (2013). Oligomeric amyloid beta induces IL-1beta processing via production of ROS: Implication in Alzheimer's disease. Cell Death &amp; Disease, 4, e975. https://doi.org/10.1038/cddis.2013.503</Citation></Reference><Reference><Citation>Pare, B., Lehmann, M., Beaudin, M., Nordstrom, U., Saikali, S., Julien, J. P., &#x2026; Gros-Louis, F. (2018). Misfolded SOD1 pathology in sporadic amyotrophic lateral sclerosis. Scientific Reports, 8(1), 14223. https://doi.org/10.1038/s41598-018-31773-z</Citation></Reference><Reference><Citation>Pasinelli, P., &amp; Brown, R. H. (2006). Molecular biology of amyotrophic lateral sclerosis: Insights from genetics. Nature Reviews. Neuroscience, 7(9), 710-723. https://doi.org/10.1038/nrn1971</Citation></Reference><Reference><Citation>Patel, M. N., Carroll, R. G., Galvan-Pena, S., Mills, E. L., Olden, R., Triantafilou, M., &#x2026; Masters, S. L. (2017). Inflammasome priming in sterile inflammatory disease. Trends in Molecular Medicine, 23(2), 165-180. https://doi.org/10.1016/j.molmed.2016.12.007</Citation></Reference><Reference><Citation>Pollari, E., Goldsteins, G., Bart, G., Koistinaho, J., &amp; Giniatullin, R. (2014). The role of oxidative stress in degeneration of the neuromuscular junction in amyotrophic lateral sclerosis. Frontiers in Cellular Neuroscience, 8, 131. https://doi.org/10.3389/fncel.2014.00131</Citation></Reference><Reference><Citation>Pramatarova, A., Laganiere, J., Roussel, J., Brisebois, K., &amp; Rouleau, G. A. (2001). Neuron-specific expression of mutant superoxide dismutase 1 in transgenic mice does not lead to motor impairment. The Journal of Neuroscience, 21(10), 3369-3374.</Citation></Reference><Reference><Citation>Prudencio, M., Hart, P. J., Borchelt, D. R., &amp; Andersen, P. M. (2009). Variation in aggregation propensities among ALS-associated variants of SOD1: Correlation to human disease. Human Molecular Genetics, 18(17), 3217-3226. https://doi.org/10.1093/hmg/ddp260</Citation></Reference><Reference><Citation>Rayamajhi, M., Zhang, Y., &amp; Miao, E. (2013). Detection of pyroptosis by measuring released lactate dehydrogenase activity. Methods in Molecular Biology (Clifton, NJ), 1040, 85-90. https://doi.org/10.1007/978-1-62703-523-1_7</Citation></Reference><Reference><Citation>Roberts, K., Zeineddine, R., Corcoran, L., Li, W., Campbell, I. L., &amp; Yerbury, J. J. (2013). Extracellular aggregated Cu/Zn superoxide dismutase activates microglia to give a cytotoxic phenotype. Glia, 61(3), 409-419. https://doi.org/10.1002/glia.22444</Citation></Reference><Reference><Citation>Rosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A., &#x2026; Brown, R. H. (1993). Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature, 362(6415), 59-62. https://doi.org/10.1038/362059a0</Citation></Reference><Reference><Citation>Rotunno, M. S., &amp; Bosco, D. A. (2013). An emerging role for misfolded wild-type SOD1 in sporadic ALS pathogenesis. Frontiers in Cellular Neuroscience, 7, 253. https://doi.org/10.3389/fncel.2013.00253</Citation></Reference><Reference><Citation>Sanz, J. M., Chiozzi, P., Ferrari, D., Colaianna, M., Idzko, M., Falzoni, S., &#x2026; Di Virgilio, F. (2009). Activation of microglia by amyloid {beta} requires P2X7 receptor expression. Journal of Immunology, 182(7), 4378-4385. https://doi.org/10.4049/jimmunol.0803612</Citation></Reference><Reference><Citation>Seetharaman, S. V., Prudencio, M., Karch, C., Holloway, S. P., Borchelt, D. R., &amp; Hart, P. J. (2009). Immature copper-zinc superoxide dismutase and familial amyotrophic lateral sclerosis. Experimental Biology and Medicine (Maywood, NJ), 234(10), 1140-1154. https://doi.org/10.3181/0903-MR-104</Citation></Reference><Reference><Citation>Sester, D. P., Zamoshnikova, A., Thygesen, S. J., Vajjhala, P. R., Cridland, S. O., Schroder, K., &amp; Stacey, K. J. (2016). Assessment of inflammasome formation by flow cytometry. Current Protocols in Immunology, 114, 14.40.11-14.40.29. https://doi.org/10.1002/cpim.13</Citation></Reference><Reference><Citation>Sibilla, C., &amp; Bertolotti, A. (2017). Prion properties of SOD1 in amyotrophic lateral sclerosis and potential therapy. Cold Spring Harbor Perspectives in Biology, 9(10), pii: a024141. https://doi.org/10.1101/cshperspect.a024141</Citation></Reference><Reference><Citation>Song, L., Pei, L., Yao, S., Wu, Y., &amp; Shang, Y. (2017). NLRP3 inflammasome in neurological diseases, from functions to therapies. Frontiers in Cellular Neuroscience, 11, 63. https://doi.org/10.3389/fncel.2017.00063</Citation></Reference><Reference><Citation>Sreedharan, J., Blair, I. P., Tripathi, V. B., Hu, X., Vance, C., Rogelj, B., &#x2026; Shaw, C. E. (2008). TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science, 319(5870), 1668-1672. https://doi.org/10.1126/science.1154584</Citation></Reference><Reference><Citation>Tschopp, J., &amp; Schroder, K. (2010). NLRP3 inflammasome activation: The convergence of multiple signalling pathways on ROS production? Nature Reviews. Immunology, 10(3), 210-215. https://doi.org/10.1038/nri2725</Citation></Reference><Reference><Citation>Urban, F. J., Jasys, J. V., Raggon, J. W., Buzon, R. A., Hill, P. D., Eggler, J. F., &amp; Weaver, J. D. (2003). Novel synthesis of 1-(1,2,3,5,6,7-Hexahydro- s-indacen-4-yl)-3-[4-(1-hydroxy-1-methyl-ethyl)-furan-2-sulfonyl]urea, an anti-inflammatory agent. Synthetic Communications, 33(12), 2029-2043. https://doi.org/10.1081/SCC-120021029</Citation></Reference><Reference><Citation>Watanabe, M., Dykes-Hoberg, M., Culotta, V. C., Price, D. L., Wong, P. C., &amp; Rothstein, J. D. (2001). Histological evidence of protein aggregation in mutant SOD1 transgenic mice and in amyotrophic lateral sclerosis neural tissues. Neurobiology of Disease, 8(6), 933-941. https://doi.org/10.1006/nbdi.2001.0443</Citation></Reference><Reference><Citation>Zhao, W., Beers, D. R., Bell, S., Wang, J., Wen, S., Baloh, R. H., &amp; Appel, S. H. (2015). TDP-43 activates microglia through NF-kappaB and NLRP3 inflammasome. Experimental Neurology, 273, 24-35. https://doi.org/10.1016/j.expneurol.2015.07.019</Citation></Reference><Reference><Citation>Zhao, W., Beers, D. R., Henkel, J. S., Zhang, W., Urushitani, M., Julien, J. P., &amp; Appel, S. H. (2010). Extracellular mutant SOD1 induces microglial-mediated motoneuron injury. Glia, 58(2), 231-243. https://doi.org/10.1002/glia.20919</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>